Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma
Shots:
- The US FDA has granted BTD to the Roche’s mosunetuzumab for the treatment of adult patients with r/r FL- prior treated with at least two systemic therapies
- The BT designation is based on P-I/Ib GO29781 study assessing mosunetuzumab in R/R non-Hodgkin lymphoma. The safety profile of the therapy was consistent with its mechanism of action
- Mosunetuzumab is an investigational CD20xCD3 T-cell engaging bispecific that targets CD20 on the surface of B-cells and CD3 on the surface of T-cells- being evaluated in clinical development program across several lymphoma indications both as monothx. and combination therapy
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com